Author + information
- Costantino R. Costantini,
- Sergio G. Tarbine,
- Costantino O. Costantini,
- Marcelo de Freitas Santos,
- Daniel Anibal Zanuttini and
- Marco Antonio Denk
The safety and performance of the Absorb Bioresorbable Vascular Scaffold (Absorb) has been previously demonstrated with clinical data. However, these trials included patients with simple lesions. Aiming to evaluate clinical outcomes, we analyzed the treatment of real world patients from a single center.
between 11/2014 and 10/2016, consecutive unselected pts. were treated with one or more Absorb BVS. Pre dilatation before stent deployment, and post dilatation, Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) were used in 99% of cases.
100 pts (88% male, mean age 58.15±9.83 yo) were included in this analysis. Diabetes was present in 31% and multivessel ds. in 52%. 32% had stable angina. A total of 141 lesions were treated (LAD 74%), being B/C class in 60%. The median SYNTAX score was 14.23±8.88 The total number of Absorb BVS implanted was 190, with an average of 1.69 per patient. Further intervention following imaging and optimization with balloon was necessary in 31 Stents (16% of cases), regarding IVUS/OCT. With 100% procedure success rate, all patients completed 30 days. 7 months mean follow up MACE showed definite/probable scaffold thrombosis in 0%, with 4% TLR, and 3% TVR.
The analysis of this cohort of patients, is showing no acute/subacute thrombosis so far, in a real world setting. Predilatation, the use of IVUS/OCT in all cases, and final balloon optimization might have impact on this outcome. 7 months mean follow up shows low MACE rate with 4% TLR and 3% TVR, caused by focal restenosis.